February 1 2017 Issue


The AARS is excited to relaunch its Hot Topics Newsletter which will now be distributed on a semi-monthly basis to Members!

Please find a brief recap of the newsletter below. The full newsletter and some relevant references are included in the Full Topics link below.

Access Hot Topics Newsletter

Be sure to tell your friends to become AARS members so they, too, can get these informative literature updates!


Industry News

  • BioPharmX will present data on its new two-photon florescence microscopy technique for visualizing minocycline skin penetration at this year's SPIE Photonics West, according to a press release. The recent BioPharmX BPX-01 phase 2a clinical trial demonstrated that the topical gel formulation delivered adequate minocycline to the appropriate site to target P. acnes.
  • Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today the approval of RHOFADE™ cream by the U.S. Food and Drug Administration (FDA) for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.
  • The first patient has been dosed in Dermata Therapeutics's Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne rosacea.

New Medical Research

  • Findings from a study to evaluate the efficacy of nanofat and platelet-rich plasma (PRP) infiltration alone and combined with fractional CO2 laser resurfacing to improve atrophic scars of the face showed subcutaneous infiltration with nanofat and PRP seems to be effective to improve atrophic scars, either alone or combined with fractional CO2 laser resurfacing.
  • A recently published article reports the draft genome sequence of an erythromycin-resistant P. acnes strain isolated from a case of folliculitis of the scalp belonging to phylotype IA1 and sequence type 18 (ST18).
  • A study to investigate a new treatment model for evaluating the antibacterial effects of lysozyme (LY)-shelled microbubbles (MBs) and ultrasound (US)-mediated LY-shelled MBs cavitation against P. acnes both in vitro and in vivo found that combined treatments of US and LY-shelled MBs can significantly reduce the treatment duration and inhibit P.-acnes-induced inflammatory skin diseases.
  • Ketoconazole may serve as an alternative treatment for acne vulgaris, which is important because the number of antibiotic-resistant P. acnes strains has been increasing, as discussed in a recent article.
  • A study to develop and analyze the antimicrobial activity of a new multi-agent, synergic formulation based on plant-derived antimicrobial compounds (i.e., eugenol, β-pinene, eucalyptol, and limonene) and anti-inflammatory agents for potential use in the topical treatment of acne and other skin infections found that the most active antimicrobial combination represented by salycilic acid/eugenol/β-pinene/2-phenoxyethanol/potassium sorbate was included in a cream base, which demonstrated thermodynamic stability and optimum microbiological characteristics.
  • Results of a clinical study demonstrated the effectiveness of an OTC 3-step, anti-acne skincare regimen in significantly improving acne and the overall appearance of skin in the majority of subjects who had mild-to-moderate acne.
  • Results from a new study indicate that the combination of the anti-inflammatory actions of colchicine and minocycline is effective in disease control in hidradenitis suppurativa (HS).
  • A randomized, double-blind, placebo-controlled, Phase 2 study showed that when compared to vehicle, SB204 2% and SB204 4% significantly decreased the absolute inflammatory lesion count and SB204 4% once daily also significantly decreased the absolute non-inflammatory lesion count in subjects with acne vulgaris treated for 12 weeks.
  • A randomized, controlled, split-face study of rosacea patients showed that radiofrequency (RF) therapy was effective in the treatment of rosacea and should be considered an alternative therapeutic option, especially in papulopustular rosacea (PPR).

Clinical Reviews

  • A recently published review highlights what is currently known regarding the use and efficacy of photodynamic therapy (PDT) using topical aminolevulinic acid (ALA) in the pediatric population. According to the review, PDT can be considered for inflammatory acne when topical treatments have failed and systemic medications are not an option.
  • The relationship between isotretinoin treatment for acne and depression is explored in a recent review.
  • A retrospective study to identify factors that contribute to depression and chronic pain in patients with hidradenitis suppurativa (HS) suggests that the extent of disease rather than severity plays a role in reducing the quality of life in HS patients.
  • Across all RCTs exclusively recruited within the United States that reported race, 74.4% of study participants were white. Disease type was significantly associated with the degree of racial diversity (P < .001) within a study cohort: 30.0% of US-based psoriasis had more than 20% racially or ethnically diverse research participants as compared with 73.9% of acne studies and 91.7% of eczema studies.
  • Dermatologist Linda Stein Gold, MD, sat down with Practical Dermatology to discuss the changing way we think about acne and what to expect from acne research in 2017.
  • A systematic review of the role of androgens and estrogens in hidradenitis suppurativa (HS) show that patients with HS do not seem to have increased levels of sex hormones and that their hormone levels lie within the normal range. While decreasing levels of progesterone and estrogen seem to coincide with disease flares in premenopausal women, the association is speculative and requires experimental confirmation.
  • Rosacea is characterized by a wide variety of vascular changes. These vascular abnormalities can be targeted with specific light and laser devices, which are reviewed in a recently published article.
  • Topical and oral strategies often used for the treatment of rosacea are reviewed and discussed in a new article.
  • The present review provides an introduction on pathogenesis and clinical manifestations of rosacea and prefers a symptom-oriented therapy approach.
  • Although there is presently no cure for rosacea, there are several recommended treatment options available to control many of the symptoms and to prevent them from getting worse, as reviewed in a recent article.

Patient Counseling / Communication

  • A small study provides evidence that recurrent pulse dye laser treatments are beneficial to rosacea patients by improving quality of life and decreasing symptoms. This finding supports the notion that chronic treatment is needed for this chronic disease.
  • A randomized, double-blind, vehicle-controlled, parallel-group, multicenter, phase 3 study was conducted in 961 participants to assess patient perception of efficacy, utility, and effect on quality of life (QOL) of an azelaic acid (AzA) 15% foam formulation for the treatment of papulopustular rosacea (PPR). Results showed that Treatment with AzA foam was associated with improved QOL and meaningful reductions in the patient-perceived burden of PPR.
  • Patient education on rosacea and appropriate treatments is an important aspect in helping patients succeed with therapy. As described in a recenet article, treatment should be tailored to each individual patient, taking into account: symptoms, trigger factors, patients' wishes, most bothersome symptoms, psychological aspect, individual needs.